Biopharmaceutical medicine is an area of huge growth and is already established as a multi-billion dollar global market. With a number of important biologics approaching their patent expiration, the biosimilar and biobetter markets have become areas of intense focus as companies invest heavily in the development of competing biotherapeutics such as monoclonal antibodies (mAbs).
Growth in this area means that cell line development is increasing in importance, with many groups involved in generating and characterising new stable cell lines. For some, cell line development is a service they provide to external groups or companies, while for others it is an integral part of their research or production process. In both cases it is extremely costly in terms of time (typically requiring 6-12 months), effort and financial expenditure.
It is crucial to isolate the right clones quickly and to produce early-stage clinical material as soon as possible. Failed clones or sub-optimal therapeutic proteins discovered at the clinical trial stage are immensely costly and the cost implications rise exponentially the further down the line the failure is detected. Accelerating and optimising the early stages of cell line development is a key factor in cost effectiveness and commercial success.
These workflows have created a need for tools such as the Cell Metric CLD™ that can address the workflow management challenges and shorten the steps in upstream cell line development in the following areas:
Click on the diagram to see how the Cell Metric CLD™ is used in the cell line development workflow.
To find out more, go to: